Yuyu Pharma

000220 · KOSPI · ₩000220 · 유유제약

₩3,690▲ ₩20 (0.54%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩4,011

vs the current price (₩3,690)

Enterprise value
₩70B
Equity value
₩74B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩1,475
−60.0%
Base
₩4,011
+8.7%
Bull
₩8,515
+130.7%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (4.5%).

Revenue growth

  • 0.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (0.5% a year, annual reports), fading to 3% by year 5.

  • 1.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (0.5% a year, annual reports), fading to 3% by year 5.

  • 1.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (0.5% a year, annual reports), fading to 3% by year 5.

  • 2.4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (0.5% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (0.5% a year, annual reports), fading to 3% by year 5.

Business

  • 4.5%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 4.1%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 5.1%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 6.1%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.13, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩144B
Net debt (borrowings and leases − cash and deposits)
−₩15B
− Minority interests
₩11B
Shares
18,337,352
incl. 2,589,890 preferred
Share price
₩3,690
Market cap
₩68B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩137B₩133B₩141B₩145B₩147B₩149B₩153B₩157B
Growth−1.2%−3.0%5.8%0.5%1.1%1.7%2.4%3.0%
EBIT₩365M₩12B₩11B₩6.5B₩6.6B₩6.7B₩6.9B₩7.1B
EBIT margin0.3%8.8%7.8%4.5%4.5%4.5%4.5%4.5%
After-tax EBIT₩264M₩8.5B₩8B₩4.7B₩4.8B₩4.9B₩5B₩5.1B
+ Depreciation———₩5.9B₩6B₩6.1B₩6.3B₩6.5B
− Capital spending₩5.1B₩7.3B₩8.5B₩7.4B₩7.5B₩7.6B₩7.8B₩8B
− Working capital₩15B−₩25B₩13B₩44M₩97M₩152M₩218M₩280M
Free cash flow———₩3.2B₩3.2B₩3.2B₩3.2B₩3.3B
Discount factor———0.9310.8670.8070.7510.700
Present value———₩3B₩2.8B₩2.6B₩2.4B₩2.3B

Terminal value ₩81B, worth ₩57B today: 81% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩7,351 a share)Now 0.50×₩4,3100.59×₩5,6530.77×₩7,5291.02×
Price / earnings (last 12 months: ₩682 a share)Now 5.41×₩3,8405.63×₩7,06010.4×₩10,68915.7×
P/E on run-rate earnings (Q2 2026 × 4: ₩796 a share)Now 4.63×₩4,4855.63×₩8,24510.4×₩12,48315.7×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩4,218₩4,530₩4,913₩5,393₩6,014
6.9%₩3,861₩4,113₩4,416₩4,787₩5,252
7.4%₩3,560₩3,767₩4,011₩4,304₩4,664
7.9%₩3,304₩3,475₩3,675₩3,911₩4,196
8.4%₩3,082₩3,226₩3,391₩3,585₩3,814

Now (TTM)

Market cap
₩58B
Enterprise value
₩42B
P/E
4.6×
P/B
0.4×
P/S
0.4×
EV/EBITDA
—
Dividend yield
3.1%

Over time (at each year end)

20252024202320222021
Price₩4,515₩4,505₩5,280₩6,220₩7,810
Market cap₩71B₩71B₩83B₩98B₩123B
P/E8.7×8.1×———
P/B0.5×0.6×0.7×0.8×1.0×
P/S0.5×0.5×0.6×0.7×1.1×
EV/EBITDA—————
Dividend yield2.5%2.2%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Yuyu Pharma4.6×0.4×0.4×—3.1%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Yuyu Pharma / 유유제약 / 000220 / KRX:000220

Source: KRX statistical information